^
    Back
    Association details:
    Biomarker:HR negative
    Cancer:HER2 Negative Breast Cancer
    Drug:carboplatin (Tubulin polymerization promoter) +
    paclitaxel (Bcl2 inhibitor, Tubulin polymerization promoter)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097, Paclitaxel, and Carboplatin Before Surgery in Treating Patients With Stage II or Stage III Triple-Negative Breast Cancer

    Excerpt:
    ......
    Trial ID:
    NCT01238133
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Cyclin dEpendent Kinase in tRiple nEGatIVe brEast canceR - a "Window of Opportunity" Study

    Excerpt:
    ...- hormone receptor-negative (2 cm;...
    Trial ID:
    CAREGIVER
    Less C2 evidence
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ESMO 2020
    Title:

    176P - Germline mutation status and therapy response in patients with homologous recombination deficient, HER2-negative early breast cancer: Results of the GeparOLA study (NCT02789332)

    Published date:
    09/14/2020
    Excerpt:
    Regardless of the treatment arm, pCR rates were higher in HR- than in HR+ pts (57.9%, 44/76 vs. 41.4%, 12/29;). We observed highest pCR rates in HR- pts with BRCA1/2 mutations (65.8%, 25/38) and lowest in HR+ pts without BRCA1/2 mutations (0%, 0/8).
    Trial ID:
    GeparOla